Design, synthesis, characterization, in vitro and in silico evaluation of novel imidazo[2,1-b][1,3,4]thiadiazoles as highly potent acetylcholinesterase and non-classical carbonic anhydrase inhibitors
作者:Sercan Askin、Hakan Tahtaci、Cüneyt Türkeş、Yeliz Demir、Abdulilah Ece、Gülşen Akalın Çiftçi、Şükrü Beydemir
DOI:10.1016/j.bioorg.2021.105009
日期:2021.8
52–54.06 nM, respectively). Besides, compound 9b inhibit hCA I up to 18-fold compared to acetazolamide, while compound 10a has a 5-fold selectivity towards hCA II. The synthesized compounds were also evaluated for their cytotoxic effects on the L929 mouse fibroblast cell line. Molecular docking simulations were performed to elucidate these inhibitors’ potential binding modes against hCA I and II isoforms
咪唑和噻二唑衍生物在药物化学中显示出广泛的应用,并且它们已被研究为用于药物化学目的的生物活性分子。经典的碳酸酐酶 (CA) 抑制剂基于磺酰胺基团,但非特异性抑制所有 CA 同工型,从而导致不良副作用,是这些类型抑制剂的主要缺点。在这里,我们报告了对新型 2,6-二取代咪唑 [2,1 -b ][1,3,4] 噻二唑衍生物(9a-k、10a和11a)和 2,5,6-三取代咪唑 [2] 的研究,1- b ][1,3,4] 噻二唑衍生物 ( 12a - 20a) 不具有用于抑制人碳酸酐酶 ( h CA, EC 4.2.1.1) I 和 II 异构体以及乙酰胆碱酯酶 (AChE, EC 3.1.1.7)的锌结合磺酰胺基团。咪唑[2,1- b ][1,3,4]噻二唑对h CA I、h CA II和AChE具有低纳摩尔抑制活性(K I s在23.44-105.50 nM、10.32-104.70 nM的范围内)和